Subscribe to Newsletter

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

 

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Content by James Strachan:

Discovery & Development Advanced Medicine

Automating Cell Therapy Manufacturing

| James Strachan

Is autologous cell therapy a realistic proposition for solid tumors?

Discovery & Development Drug Discovery

Completing the Cell Therapy Revolution

| James Strachan

The question that’s on everyone’s lips: how can developers tackle solid tumors and bring cell therapy to millions?

Discovery & Development Drug Discovery

Unleashing Cellular Potential

| James Strachan

Epigenetic switches are being used to identify the optimal combination of transcription factors required to derive clinically valuable cell types.

Business & Regulation Standards & Regulation

Watching the Future

| James Strachan

We sit down to interview Peter Marks, Director of the Center for Biologics Evaluation and Research at the US FDA.

Business & Regulation Profession

People, Process, Product: Lessons Learned with Antoinette Gawin

| James Strachan

Find out how a random act of kindness set Antoinette Gawin on the path to becoming a VP in her twenties.

Business & Regulation COVID-19

COVID-19: Inside the UK's Vaccine Taskforce

| James Strachan

Steve Bates gives us the inside scoop on the UK’s Vaccine Taskforce.

Business & Regulation Drug Delivery

What's New from The Cell + Gene Curator?

| James Strachan

History was made this past month as China's National Medical Products Administration approved the country's first CAR T-cell therapy: Yescarta.

Discovery & Development Advanced Medicine

Understanding the Three Levels of Genetic Medicine

| James Strachan

Care must be taken to ensure patients understand the difference between gene therapy and the different kinds of gene editing.

Business & Regulation Business Practice

How to Plug the Skills Gap

| James Strachan

Experts from the BIA got together to discuss how the UK’s biotechnology industry can plug the UK’s worrying skills gap.

Discovery & Development Advanced Medicine

What's New from the Cell + Gene Curator?

| James Strachan

What was described by a University of California professor as gene therapy's "single most remarkable achievement?"

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register